title: [Pregabalin should be moved to the prescription group B].
authors.affiliation: Avdeling for klinisk farmakologi, St. Olavs hospital, Norway. andreas.westin@legemidler.no
authors.forename: Andreas Austgulen
authors.initials: AA
authors.lastname: Westin
authors.forename: Jørgen G
authors.initials: JG
authors.lastname: Bramness
authors.forename: Fatemeh
authors.initials: F
authors.lastname: Chalabianloo
authors.forename: Tarjei
authors.initials: T
authors.lastname: Rygnestad
authors.forename: Lars
authors.initials: L
authors.lastname: Slørdal
mesh_terms: D000700:Analgesics / Q000009:adverse effects / Q000191:economics; D000927:Anticonvulsants / Q000009:adverse effects / Q000191:economics; D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence*; D006801:Humans; D000069583:Pregabalin; D055553:Prescription Drugs / Q000592:standards; D019966:Substance-Related Disorders / Q000209:etiology; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000191:economics
chemical_list: D000700:Analgesics; D000927:Anticonvulsants; D055553:Prescription Drugs; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid